Last updated: July 31, 2026
Bethanechol chloride is a mature, low-cost generic cholinergic drug used primarily for postoperative urinary retention and neurogenic bladder atony. Its commercial market is fragmented, largely generic, and exposed to limited patent or regulatory exclusivity. The originator brand Urecholine has lost practical market relevance, while current value is concentrated in low-margin prescription tablets and institutional supply channels. Public companies do not generally report bethanechol-specific revenue, so financial analysis depends on product availability, pricing, supplier participation, and prescription demand rather than disclosed sales figures.
What is bethanechol chloride used for?
Bethanechol chloride is a direct muscarinic cholinergic agonist. It stimulates bladder detrusor contraction and gastrointestinal smooth-muscle activity without producing clinically important nicotinic effects at therapeutic doses.
The U.S. label identifies these indications:
- Acute postoperative and postpartum nonobstructive urinary retention
- Neurogenic bladder atony with urinary retention
- Postoperative abdominal distention
- Gastric atony in selected clinical settings
The drug is administered orally or subcutaneously. The label warns against intravenous or intramuscular administration because of the risk of severe cholinergic reactions. Contraindications include hyperthyroidism, peptic ulcer disease, bronchial asthma, coronary artery disease, bradycardia, hypotension, vasomotor instability, epilepsy, Parkinsonism, and mechanical obstruction of the gastrointestinal or urinary tract [1].
Bethanechol is not a treatment for benign prostatic hyperplasia when mechanical obstruction is present. Its use is most commercially relevant in acute-care, urology, postoperative, and long-term-care settings.
What is the FDA regulatory status of bethanechol chloride?
Bethanechol chloride is an approved prescription drug marketed primarily through abbreviated new drug applications and legacy generic approvals.
| Regulatory attribute |
Market position |
| Active ingredient |
Bethanechol chloride |
| Drug class |
Direct-acting muscarinic agonist |
| Primary dosage forms |
Oral tablets; injectable products have historically been marketed |
| Common tablet strengths |
5 mg, 10 mg, 25 mg, and 50 mg |
| Prescription status |
Prescription-only |
| FDA pathway for current suppliers |
Primarily generic approvals under ANDA or legacy approval pathways |
| Reference brand |
Urecholine |
| Current originator position |
Commercially limited or discontinued |
| Pediatric status |
Not a major pediatric market |
| Biosimilar pathway |
Not applicable |
The U.S. market is dominated by generic products. A current product’s regulatory status depends on the specific manufacturer, strength, package configuration, and listing status in FDA databases. Product availability can change when a supplier discontinues a strength or exits the market.
Bethanechol’s clinical market is small compared with contemporary urology drugs such as tamsulosin, mirabegron, vibegron, and antimuscarinic agents. Its use is generally episodic or specialist-directed rather than chronic, high-volume maintenance therapy.
What patents protect bethanechol chloride?
No meaningful active composition-of-matter patent estate protects bethanechol chloride in the United States. The active ingredient has been used clinically for decades, and any original compound patent rights expired long ago.
Patent-estate assessment
| Patent category |
Commercial relevance |
| Compound patent |
Expired |
| Core composition patent |
No practical current protection |
| Brand patent estate |
No material current barrier |
| Formulation patents |
Limited commercial significance |
| Method-of-use patents |
No known blocking modern exclusivity position |
| Manufacturing patents |
Potentially relevant to individual suppliers but not a market-wide barrier |
| Pediatric exclusivity |
Not a current market driver |
| Orphan-drug exclusivity |
Not applicable |
| New chemical entity exclusivity |
Expired decades ago |
Bethanechol is not a biologic, so biosimilar regulation does not apply. Competition occurs through generic drug approval, manufacturing capacity, wholesaler access, and reimbursement economics.
What is the Orange Book status of bethanechol chloride?
The Orange Book’s commercial significance for bethanechol is limited because the market does not depend on an active brand patent or an unexpired regulatory exclusivity period.
The relevant Orange Book issues are:
- Whether a specific reference-listed product remains commercially marketed.
- Whether a generic product is listed as therapeutically equivalent to the reference product.
- Whether an individual dosage form or strength remains available.
- Whether a discontinued product remains listed for historical regulatory purposes.
A discontinued brand listing does not create a patent barrier. FDA’s discontinued-drug records distinguish commercial discontinuation from withdrawal for safety or effectiveness reasons [2].
No current Paragraph IV campaign is widely associated with bethanechol chloride. The product’s age, low commercial value, and absence of a valuable patent estate reduce the incentive for ANDA filers to challenge patents.
When does bethanechol chloride lose exclusivity?
Bethanechol chloride lost meaningful exclusivity many years ago. Its U.S. market is already open to generic competition.
Exclusivity timeline
| Period |
Market development |
| Mid-20th century |
Bethanechol introduced as a cholinergic therapy |
| Legacy brand period |
Urecholine became the best-known U.S. brand |
| Generic-entry period |
Multiple manufacturers entered with bethanechol chloride products |
| Post-exclusivity period |
Price competition and supplier turnover became the main market forces |
| Current market |
Generic, low-growth, low-margin market with intermittent supply risk |
There is no commercially relevant future “loss of exclusivity” date comparable to the patent cliffs for newer branded drugs. The key question is whether manufacturers continue to supply each dosage strength at economically viable prices.
How many patents cover bethanechol chloride?
There is no material active U.S. patent portfolio that covers the core bethanechol chloride market. Historical patents may appear in patent databases, but they do not create current market exclusivity.
The remaining IP risk is supplier-specific:
- Manufacturing process claims
- Tablet-compression or coating technology
- Packaging technology
- Combination products
- Private contractual restrictions
- Trade secrets concerning cost-efficient production
These rights would generally affect a particular manufacturer rather than prevent generic supply across the market. A process patent could create litigation exposure for one supplier, but it would not normally restore branded pricing power for bethanechol as a molecule.
What formulations are protected by bethanechol chloride patents?
No formulation category has established a major current exclusivity position for bethanechol chloride in the United States.
The principal commercial formulations are conventional immediate-release tablets. They do not require complex delivery technology, controlled-release polymers, device platforms, or biologic manufacturing. This limits the opportunity for differentiated formulation pricing.
Historically marketed injectable forms have a different supply profile because sterile manufacturing creates higher compliance and production costs. Injectable products may experience more supply volatility than oral tablets, but that vulnerability arises from manufacturing economics and facility capacity, not from active formulation patents.
Which companies manufacture or market bethanechol chloride?
The U.S. supply base has included generic pharmaceutical companies, contract manufacturers, repackagers, and institutional distributors. Product listings have historically appeared under companies such as American Health Packaging, Major Pharmaceuticals, Rising Pharmaceuticals, and other generic or repackaging entities, depending on the product strength and period reviewed.
Manufacturing and distribution are often separated:
- A contract manufacturer produces the tablets.
- A generic company holds or sponsors the application.
- A repackager supplies hospitals, pharmacies, and long-term-care facilities.
- A wholesaler distributes the product under private-label or institutional packaging.
This structure makes market-share analysis difficult. A company appearing on a package may not be the actual manufacturer, and a product listing may remain in a database after commercial supply has ended.
What is the financial trajectory for bethanechol chloride?
Bethanechol chloride has a low and mature financial profile. The product is unlikely to generate material revenue for diversified pharmaceutical companies, and public filings generally do not disclose product-level sales.
Revenue drivers
| Driver |
Effect on bethanechol economics |
| Generic competition |
Suppresses unit price |
| Low clinical growth |
Limits volume expansion |
| Few suppliers |
Can produce temporary price increases |
| Hospital demand |
Supports recurring institutional orders |
| Retail demand |
Remains dependent on sporadic prescriptions |
| Manufacturing complexity |
Higher for sterile products than tablets |
| Reimbursement |
Favors low-cost generic sourcing |
| Brand substitution |
Limits premium pricing |
Revenue is likely concentrated in a small number of suppliers during periods when competitors exit or experience production interruptions. That concentration can raise short-term prices without creating durable long-term profitability.
Bethanechol does not have the characteristics of a high-growth pharmaceutical asset. It has no active patent runway, no meaningful label expansion program, and no biologic or specialty-pharmacy channel. The commercial opportunity is primarily operational: maintaining reliable supply, securing low-cost manufacturing, and capturing institutional contracts.
How strong is the patent estate for bethanechol chloride?
The patent estate is weak from an exclusivity perspective but relatively simple from a freedom-to-operate perspective.
Strength assessment
| Criterion |
Assessment |
| Core molecule protection |
None of current commercial value |
| Patent duration |
Fully expired for practical purposes |
| Formulation differentiation |
Low |
| Regulatory exclusivity |
None of current commercial significance |
| Generic entry risk |
Minimal because entry is already established |
| Litigation risk |
Low at the molecule level |
| Supply-chain risk |
More important than patent risk |
| Pricing power |
Low |
| Licensing value |
Limited |
A buyer evaluating bethanechol assets should focus on the approved product portfolio, manufacturing economics, supplier reliability, and customer contracts. Patent diligence remains necessary to identify supplier-specific process or formulation claims, but it is not the primary valuation issue.
What generic entry risks exist for bethanechol chloride?
Generic entry risk is already realized. The principal commercial risks are reverse forms of generic competition:
- A new low-cost supplier can reduce prices.
- A current supplier can discontinue a product.
- A manufacturer can lose access to an active pharmaceutical ingredient.
- A wholesaler can substitute another supplier.
- A shortage can temporarily increase prices.
- Hospital formularies can replace bethanechol with alternative therapies.
- Prescribers can favor catheterization, alpha blockers, or other management strategies.
The low price of tablets limits the value of incremental entrants. A generic company may avoid the product if expected annual revenue does not justify FDA maintenance, pharmacovigilance, quality, and distribution costs.
What patent litigation and Paragraph IV challenges affect bethanechol chloride?
No major current U.S. patent litigation or Paragraph IV dispute is associated with bethanechol chloride’s core market. The lack of an active patent estate removes the principal basis for a conventional Hatch-Waxman patent challenge.
Potential disputes would more likely involve:
- ANDA approval or product-specific regulatory issues
- Manufacturing defects
- Labeling disputes
- Trademark or trade-dress matters
- Supplier contracts
- Antitrust allegations involving distribution or shortage pricing
These issues would be narrower than the patent litigation typically seen with branded small molecules approaching generic entry.
Are there licensing deals for bethanechol chloride?
Bethanechol chloride has limited licensing value because the molecule is off-patent and the product is commercially mature. Licensing transactions, if they occur, are more likely to involve:
- A generic application
- A contract manufacturing agreement
- A regional distribution arrangement
- A private-label supply contract
- A portfolio acquisition involving multiple low-volume products
A standalone royalty-bearing license for the active ingredient would be commercially unusual. The value of a transaction would depend on supply rights, approved strengths, manufacturing cost, and customer access rather than patent exclusivity.
How does bethanechol compare with competing urinary-retention drugs?
Bethanechol occupies a narrow position in the urinary-retention market.
| Drug or class |
Main use |
Patent and market position |
Commercial comparison |
| Bethanechol |
Bladder atony and nonobstructive retention |
Mature generic |
Low price, limited volume |
| Tamsulosin |
BPH and urinary symptoms |
Mature generic |
Larger chronic-use market |
| Mirabegron |
Overactive bladder |
Branded and generic competition |
Higher-value specialty market |
| Vibegron |
Overactive bladder |
Newer branded/generic transition |
Higher pricing potential |
| Oxybutynin |
Overactive bladder |
Mature generic |
Broad but side-effect-limited use |
| Catheterization |
Mechanical bladder emptying |
Procedure rather than drug |
Often substitutes for drug therapy |
Bethanechol is not a direct substitute for every urinary-retention treatment. It is most relevant when detrusor underactivity is present and mechanical obstruction has been excluded. Its clinical niche limits demand but also preserves a baseline market among hospitals, urologists, and long-term-care providers.
What geographic markets matter for bethanechol chloride?
The United States is a generic, low-price market with fragmented supply. International markets vary according to national formularies, local manufacturing, hospital procurement, and whether oral or injectable products are registered.
Commercial opportunities are strongest where:
- A national formulary retains bethanechol;
- Local suppliers have exited;
- Hospital procurement is concentrated;
- Regulatory registration can be maintained at low cost;
- Import dependence creates recurring supply gaps.
The absence of meaningful patent protection means geographic barriers are mainly regulatory and commercial. A company entering a foreign market must secure local authorization, comply with manufacturing standards, and establish distribution. Patent clearance is generally less important than registration and supply continuity.
What manufacturing and intellectual-property barriers affect supply?
Manufacturing barriers are more important than patent barriers. Oral bethanechol tablets are technically uncomplicated, but low demand can make production inefficient. Manufacturers must maintain validated processes, quality systems, stability data, active pharmaceutical ingredient supply, and batch-release controls for a low-revenue product.
The main risks are:
- API supplier concentration
- Small production runs
- Low inventory incentives
- Packaging and labeling costs
- Quality-control testing
- Facility scheduling
- FDA inspection findings
- Wholesaler purchasing concentration
Sterile injectable manufacturing adds facility, validation, and contamination-control requirements. These constraints can reduce the number of viable suppliers even when no patent prevents entry.
Key Takeaways
- Bethanechol chloride is a mature, off-patent generic cholinergic drug.
- Urecholine no longer provides meaningful commercial exclusivity.
- No active core patent estate or major Paragraph IV challenge drives the market.
- The principal U.S. products are conventional tablets, with oral strengths historically including 5 mg, 10 mg, 25 mg, and 50 mg.
- Public companies generally do not disclose bethanechol-specific revenue.
- Financial value is low and depends on supply reliability, institutional contracts, and temporary supplier shortages.
- Manufacturing capacity and API access are more important than intellectual-property protection.
- The drug has limited growth potential and no meaningful biosimilar exposure.
- Generic-entry risk is already realized; the more relevant risk is supplier exit and product discontinuation.
- Licensing value is limited unless attached to an approved application, manufacturing platform, or distribution network.
Frequently Asked Questions
Is bethanechol chloride still available in the United States?
Generic bethanechol chloride products have been marketed in the United States, but availability varies by strength, supplier, package size, and time period. Product-level FDA and DailyMed listings are the controlling sources for current market status [2, 3].
Is bethanechol chloride a branded or generic drug?
Bethanechol chloride is primarily a generic drug. Urecholine is the historical reference brand associated with the molecule, but current commercial activity is concentrated in generic and institutional products.
Does bethanechol chloride have biosimilar competition?
No. Bethanechol chloride is a chemically synthesized small molecule, not a biologic. Competition occurs through generic-drug approval rather than the biosimilar pathway.
Can a company obtain a new patent on bethanechol chloride?
A new patent cannot restore expired composition-of-matter protection for the known molecule. A company could seek patent protection for a genuinely novel formulation, manufacturing process, combination, or new use if statutory patent requirements are met, but such rights would not automatically block conventional generic tablets.
Is bethanechol chloride commercially attractive for a pharmaceutical acquisition?
As a standalone asset, bethanechol chloride has limited strategic value. It may have value as part of a broader generic portfolio, particularly where the buyer has manufacturing capacity, hospital contracts, or a distribution platform that can support low-volume products.
References
-
DailyMed. (n.d.). Bethanechol chloride tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. National Library of Medicine. (n.d.). DailyMed: Bethanechol chloride drug labels. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Approved drug product list and discontinued drug product database. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-database-oral-solid-dosage-forms-and-other-products/approved-drug-products-with-therapeutic-equivalence-evaluations-orange-book
